Allergan Announces Commercialization Collaboration With McNeil Consumer Healthcare.

IRVINE, Calif.--(BW HealthWire)--Sept. 14, 1999--

Allergan, Inc. (NYSE: AGN) announced today that it has entered into a multi-year agreement with McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson (NYSE: JNJ), to commercialize Allergan's proprietary anti-infective, Ocuflox(R) (ofloxacin ophthalmic solution 0.3%), in the U.S. pediatric and selected general practitioner markets. Ocuflox(R) was launched by Allergan in 1993 and has become the most prescribed ocular anti-infective by ophthalmologists in the United States. McNeil's salesforce began detailing and promoting Ocuflox(R) to its practitioner base in early September.

"Allergan is very excited about this co-promotion arrangement with McNeil Consumer Healthcare, the largest consumer and prescription pediatric company in the United States" said David E.I. Pyott, President and Chief Executive Officer of Allergan. "The relationship with McNeil provides Allergan with an established, highly respected marketing partner committed to making Ocuflox(R) commercially successful in the pediatric market. McNeil's experience, and its related success, with the marketing of Floxin(R), the Otic version of ofloxacin, will facilitate the launch of Ocuflox(R) in the pediatric market," continued Mr. Pyott. "Furthermore, this transaction is illustrative of Allergan's desire to both focus on our core customers, the ophthalmologist, and gain access to significant alternative physician audiences."

Forward-looking Statements

Any of the above statements that refer to Allergan's estimated or anticipated future results or product performance are forward-looking and reflect the Company's current analysis of existing trends and information. Actual results may differ from current expectations based on a number of factors affecting Allergan's businesses, including new product performance, competitive conditions and products, changing market conditions, the success of the collaboration with McNeil and the level of Ocuflox(R) acceptance in the pediatric and selected general practitioner markets. In addition, matters generally affecting the economy, such as currency exchange rates and the state of the economy worldwide, can affect the Company's results. These forward-looking statements represent the Company's judgment only as of the date of this press release. Actual results could differ materially from expectations reflected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements. The Company disclaims any intent or obligation to update these forward-looking statements.

Additional information concerning these factors can be found in press releases as well as in Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting Business" in Allergan's 1998 Form 10-K. These filings are available publicly and upon request from Allergan's Investor Relations Department: 714-246-4636 or on the internet at http://www.allergan.com.

Allergan, Inc. headquartered in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet medical needs and improve patients' lives.